• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Xilio Therapeutics Inc.

    12/11/25 5:55:21 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XLO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Xilio Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    98422T100

    (CUSIP Number)


    12/04/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    98422T100


    1Names of Reporting Persons

    Coastlands Capital LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,346,069.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,346,069.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,346,069.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA, PN

    Comment for Type of Reporting Person:  The calculation of the beneficial ownership of the Reporting Persons is based on (i) 52,500,328 shares of Common Stock issued and outstanding as of November 11, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2025, and (ii) 1,013,882 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 9.99%. Excludes pre-funded warrants held by the Reporting Persons in excess of such beneficial ownership limitation and Common Stock warrants held by the Reporting Persons with a beneficial ownership limitation of 4.99%.


    SCHEDULE 13G

    CUSIP No.
    98422T100


    1Names of Reporting Persons

    Coastlands Capital Partners LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,346,069.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,346,069.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,346,069.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  The calculation of the beneficial ownership of the Reporting Persons is based on (i) 52,500,328 shares of Common Stock issued and outstanding as of November 11, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2025, and (ii) 1,013,882 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 9.99%. Excludes pre-funded warrants held by the Reporting Persons in excess of such beneficial ownership limitation and Common Stock warrants held by the Reporting Persons with a beneficial ownership limitation of 4.99%.


    SCHEDULE 13G

    CUSIP No.
    98422T100


    1Names of Reporting Persons

    Coastlands Capital GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,346,069.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,346,069.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,346,069.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  The calculation of the beneficial ownership of the Reporting Persons is based on (i) 52,500,328 shares of Common Stock issued and outstanding as of November 11, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2025, and (ii) 1,013,882 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 9.99%. Excludes pre-funded warrants held by the Reporting Persons in excess of such beneficial ownership limitation and Common Stock warrants held by the Reporting Persons with a beneficial ownership limitation of 4.99%.


    SCHEDULE 13G

    CUSIP No.
    98422T100


    1Names of Reporting Persons

    Coastlands Capital LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,346,069.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,346,069.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,346,069.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, OO

    Comment for Type of Reporting Person:  The calculation of the beneficial ownership of the Reporting Persons is based on (i) 52,500,328 shares of Common Stock issued and outstanding as of November 11, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2025, and (ii) 1,013,882 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 9.99%. Excludes pre-funded warrants held by the Reporting Persons in excess of such beneficial ownership limitation and Common Stock warrants held by the Reporting Persons with a beneficial ownership limitation of 4.99%.


    SCHEDULE 13G

    CUSIP No.
    98422T100


    1Names of Reporting Persons

    Matthew D. Perry
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,346,069.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,346,069.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,346,069.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The calculation of the beneficial ownership of the Reporting Persons is based on (i) 52,500,328 shares of Common Stock issued and outstanding as of November 11, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2025, and (ii) 1,013,882 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 9.99%. Excludes pre-funded warrants held by the Reporting Persons in excess of such beneficial ownership limitation and Common Stock warrants held by the Reporting Persons with a beneficial ownership limitation of 4.99%.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Xilio Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    828 Winter Street Suite 300 Waltham, MA, 02451
    Item 2. 
    (a)Name of person filing:

    Coastlands Capital LP, a Delaware limited partnership ("Coastlands") Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership") Coastlands Capital GP LLC, a Delaware limited liability company (the "General Partner") Coastlands Capital LLC, a Delaware limited liability company ("Coastlands GP") Matthew D. Perry Coastlands and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Coastlands GP is the general partner of Coastlands. Mr. Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    601 California Street, Suite 1210, San Francisco, CA 94108
    (c)Citizenship:

    See Item 4 of the cover sheet for each reporting person.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    98422T100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Coastlands: 5,346,069 Partnership: 5,346,069 General Partner: 5,346,069 Coastlands GP: 5,346,069 Matthew D. Perry: 5,346,069
    (b)Percent of class:

    Coastlands: 9.99% Partnership: 9.99% General Partner: 9.99% Coastlands GP: 9.99% Matthew D. Perry: 9.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Coastlands: 0 Partnership: 0 General Partner: 0 Coastlands GP: 0 Matthew D. Perry: 0

     (ii) Shared power to vote or to direct the vote:

    Coastlands: 5,346,069 Partnership: 5,346,069 General Partner: 5,346,069 Coastlands GP: 5,346,069 Matthew D. Perry: 5,346,069

     (iii) Sole power to dispose or to direct the disposition of:

    Coastlands: 0 Partnership: 0 General Partner: 0 Coastlands GP: 0 Matthew D. Perry: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Coastlands: 5,346,069 Partnership: 5,346,069 General Partner: 5,346,069 Coastlands GP: 5,346,069 Matthew D. Perry: 5,346,069

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Partnership holds the shares of Common Stock, including shares of Common Stock issuable upon exercise of pre-funded warrants and Common Stock warrants, for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, shares of Common Stock, including shares of Common Stock issuable upon exercise of pre-funded warrants and Common Stock warrants.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Coastlands Capital LP
     
    Signature:/s/ Mark Shamia
    Name/Title:Chief Operating Officer of the General Partner, Coastlands Capital LLC
    Date:12/11/2025
     
    Coastlands Capital Partners LP
     
    Signature:/s/ Mark Shamia
    Name/Title:Chief Operating Officer of the General Partner, Coastlands Capital GP LLC
    Date:12/11/2025
     
    Coastlands Capital GP LLC
     
    Signature:/s/ Mark Shamia
    Name/Title:Chief Operating Officer
    Date:12/11/2025
     
    Coastlands Capital LLC
     
    Signature:/s/ Mark Shamia
    Name/Title:Chief Operating Officer
    Date:12/11/2025
     
    Matthew D. Perry
     
    Signature:/s/ Matthew D. Perry
    Name/Title:Reporting person
    Date:12/11/2025
    Exhibit Information

    Exhibit 99.1 - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G

    Get the next $XLO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XLO

    DatePrice TargetRatingAnalyst
    8/6/2025$2.00Outperform
    Leerink Partners
    12/21/2022$7.00Buy
    Chardan Capital Markets
    1/10/2022$36.00Buy
    HC Wainwright & Co.
    11/16/2021$40.00Buy
    Guggenheim
    11/16/2021$31.00Outperform
    Raymond James
    11/16/2021Outperform
    Cowen & Co.
    11/16/2021$32.00Overweight
    Morgan Stanley
    More analyst ratings

    $XLO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Xilio Therapeutics Inc.

    SCHEDULE 13G - Xilio Therapeutics, Inc. (0001840233) (Subject)

    12/11/25 5:55:21 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Xilio Therapeutics Inc.

    S-8 - Xilio Therapeutics, Inc. (0001840233) (Filer)

    11/25/25 4:16:40 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

    11/25/25 4:05:26 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

    Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden  Presented Phase 1 data at SITC for efarindodekin alfa showing promising monotherapy anti-tumor activity and generally well-tolerated safety profile in patients with advanced solid tumors Announced new preclinical data at SITC for masked T cell engager programs supporting best-in-class potential and showing efficient masking, potent anti-tumor activity and broad therapeutic index Anticipate cash runway into the first quarter of 2027 WALTHAM, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Xilio Therap

    11/13/25 7:30:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

    40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need Company to host conference call and webcast on Monday, November 10, 2025, at 4:30 p.m. ET with leading cancer experts to review the data WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced new data from its ongoing Phase 2 clinical trial evaluating vilas

    11/7/25 9:05:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

    Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio's ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, demonstrated promising monotherapy anti-tumor activity in patients with advanced solid tumors and generally well-tolerated safety profile Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, show potential for ctDNA as an early predictor for response to treatment with vilastobart in combination with atezolizumab in patients with MSS mCRC WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -

    11/7/25 9:01:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shannon James Samuel bought $48,085 worth of shares (70,000 units at $0.69) (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:57:19 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Russo Rene bought $24,680 worth of shares (36,289 units at $0.68), increasing direct ownership by 15% to 281,172 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    6/18/25 4:56:47 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gilead Sciences, Inc. bought $1,830,377 worth of shares (1,759,978 units at $1.04), increasing direct ownership by 24% to 9,105,451 units (SEC Form 4)

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    12/19/24 4:19:34 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Xilio Therapeutics Inc.

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    12/1/25 4:36:41 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by SVP, FINANCE AND ACCOUNTING Brennan Kevin M.

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    11/25/25 4:10:06 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Frankenfield Christopher James

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    11/25/25 4:10:06 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Xilio Therapeutics with a new price target

    Leerink Partners initiated coverage of Xilio Therapeutics with a rating of Outperform and set a new price target of $2.00

    8/6/25 7:25:30 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Xilio Therapeutics with a new price target

    Chardan Capital Markets initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $7.00

    12/21/22 7:57:28 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Xilio Therapeutics with a new price target

    HC Wainwright & Co. initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $36.00

    1/10/22 6:12:33 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Leadership Updates

    Live Leadership Updates

    View All

    Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

    CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also currently serves as Chief Executive Officer of Timberlyne Therapeutics, a clinical-stage company focused on the development and commercialization of transformational therapies for autoimmune diseases. "Da

    8/4/25 8:03:00 AM ET
    $CPRX
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

    WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company's board of directors. "Tunde is an accomplished leader with a strong track record of successfully developing novel therapies across a broad range of therapeutic areas, including several important cancer immunotherapies for anti-CTLA-4, PD-1 and T-cell engager through all stages of development, and I am thrilled to welcome him to the board," said Paul Clancy, chair of the board of dire

    6/10/25 4:30:00 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

    Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T cell engager programs in novel ATACR and SEECR formats for PSMA, CLDN18.2 and STEAP1 Announced collaboration with AbbVie in the first quarter of 2025 to develop novel tumor-activated, antibody-based immunotherapies, including masked T cell engagers WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipe

    3/11/25 7:30:58 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Financials

    Live finance-specific insights

    View All

    Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

    40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need Company to host conference call and webcast on Monday, November 10, 2025, at 4:30 p.m. ET with leading cancer experts to review the data WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced new data from its ongoing Phase 2 clinical trial evaluating vilas

    11/7/25 9:05:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

    Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended anticipated cash runway into the first quarter of 2026 Company to host investor conference call and webcast today at 8:30 am ET WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane antigen (PSMA), claudi

    2/12/25 7:35:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

    Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging X

    2/12/25 7:33:00 AM ET
    $ABBV
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 5:44:28 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 4:30:23 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/12/24 4:50:36 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care